Arcadia Biosciences (NASDAQ:RKDA) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Thursday. The firm set a “sell” rating on the basic materials company’s stock.

RKDA has been the subject of a number of other research reports. Lake Street Capital upgraded shares of Arcadia Biosciences to a “strong-buy” rating in a report on Tuesday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Arcadia Biosciences in a research note on Friday, April 5th.

Arcadia Biosciences Stock Performance

RKDA opened at $2.93 on Thursday. The stock’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.62. Arcadia Biosciences has a one year low of $1.85 and a one year high of $5.60. The stock has a market cap of $3.98 million, a price-to-earnings ratio of -0.57 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.74. Arcadia Biosciences had a negative return on equity of 84.27% and a negative net margin of 129.74%. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.20 million. During the same quarter in the prior year, the company posted ($3.83) EPS. As a group, analysts predict that Arcadia Biosciences will post -5.01 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.